Eplerenone aldosterone blockade

Description Results

death from any cause 0.86 [0.77; 0.96]

death from cardiovascular causes 0.84 [0.74; 0.95]

Sudden death 0.80 [0.66; 0.98]

death from cardiovascular causes or hospitalization for cardiovascular causes 0.89 [0.82; 0.96]

serious hyperkalemia (¡Ý6.0 mmol per liter) 1.43 [1.14; 1.78]

Adverse events 0.99 [0.97; 1.02]

hospitalisation for cardiovascular causes 0.93 [0.84; 1.03]

death from any cause 0.81 [0.67; 0.97]

death from cardiovascular causes 0.80 [0.65; 0.98]

Death from any cause or hospitalization for any reason 0.82 [0.74; 0.90]

Hospitalization for heart failure 0.65 [0.54; 0.78]

Hospitalization for any reason 0.84 [0.75; 0.93]

Death from any cause or hospitalization for heart failure 0.72 [0.63; 0.83]

serious hyperkalemia (¡Ý6.0 mmol per liter) 2.19 [1.58; 3.04]

Death from worsening heart failure 0.74 [0.51; 1.08]

Adverse events 0.98 [0.93; 1.02]

Sudden death 0.79 [0.57; 1.11]

eplerenone 25 mg per day initially, titrated to amaximum of 50 mg per day (n=3319)

vs.

placebo (n=3313)

Double blind

Parallel groups

Sample size: 3319/3313

Primary endpoint: all cause death AND cardiovascular death or hospitalization for a CV event

FU duration: 16 mo (mean, range 0 to 33)

eplerenone (n=1364)

vs.

placebo (n=1373)

double blind

Parallel groups

Sample size: 1364/1373

Primary endpoint: CV death, hospitalization for HF

FU duration: 21 months